CUMYL PICA

CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006. It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers. CUMYL-PICA acts as a potent agonist for the cannabinoid receptors, with approximately 20x selectivity for CB₁, having an EC₅₀ of 0.66nM for human CB₁ receptors and 13nM for human CB₂ receptors.